Original InvestigationNeuron-Specific Enolase as a Predictor of Death or Poor Neurological Outcome After Out-of-Hospital Cardiac Arrest and Targeted Temperature Management at 33°C and 36°C
Key Words
Abbreviations and Acronyms
Cited by (0)
The TTM-Trial was funded by independent research grants from the Swedish Heart Lung Foundation; Arbetsmarknadens Försäkringsaktiebolag Insurance Foundation; Swedish Research Council; regional research support, Region Skåne; governmental funding of clinical research within the Swedish National Health Services; Thelma Zoega Foundation; Krapperup Foundation; Thure Carlsson Foundation; Hans-Gabriel and Alice Trolle-Wachtmeister Foundation for Medical Research; Skåne University Hospital, Sweden; TrygFonden, Denmark; the European Clinical Research Infrastructures Network; and the European Critical Care Research Network. There was no commercial funding. Funding organizations neither had any access to the data nor had any influence on the analysis or interpretation. Drs. Collignon and Devaux have received support from the Ministry of Higher Education and Research of Luxembourg and National Research Fund. Dr. Wise has served on the advisory board of Bard Medical. Dr. Erlinge has received speakers fees from ZOLL and Philips. Drs. Nielsen and Pellis have received speaker fees from Bard Medical. Dr. Erlinge has received speaker fees from Zoll and Philips. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.